Stock info Tubize-Fin | Filter  Basic-Info

Tubize-Fin or Financiere De Tubize is a pharma R&D company which has majority of share holdings in UCB SA (one of the best pharmaceutical industry) on a global basis. The company is mainly engaged in researching, developing and commercializing the products of pharmaceuticals, which can be strengthened to be used as one of the best therapeutic treatment in the areas of CNS (central nervous system) and immunology related diseases. The company has been headquartered in Brussels, Belgium, having Mr François Tesch as the President.

A large number of Pharmaceuticals and Biotechnology shares get affected by the trading features of this company, which are traded on the continuous markets of NYSE Euronext stock exchange in Brussels with a number reaching out to around 44 million. Comparing the data of 2011 and 2012 of the revenue counts of the company gives a detailed presentation of a un-consolidated balancing sheet of 1,581,040,218 € (2012) as against 1,581,629,606 € (2011). The overall assets get a consolidated increase reaching 1,785,998 K € (2012) as against 1,824,404 K € (2011). So, in turn overall stock holder equity in the year of 2012 was 1,295, in which 36.20 % shares were of biopharmaceutical company UCB, having an industry of 4000 working strength in the health care sector.

All the products have been divided into two of the main categories i.e. CNS and immunological section. CNS segmentation includes a large number of products starting from ‘Keppra’ – used for the treatment of partially on-setting of fits in infants, children and adults; ‘Neupro’ for treating of indications and symptoms of early stage Parkinson's disease and also adult’s rest-less legs disorders; ‘Metadate’ for treatment of ADHD (Attention Deficit Hyperactivity Disorder); ‘Nootropil’ for treating dizziness and other indications that comes with ageing or oldness; ‘Xyrem’ (sodium oxybate drug), a medicine for the treatment of narco-lepsy with cataplexy in adults; and at last - ‘Vimpat’ as one of the drug providing indication from the partially on-setting of fits.

The second segmentation or we can say division is the Immunological Disorders including – ‘Cimzia’ as the first medicine to be described here, used for the treatment of Crohn’s disease and urticaria along with allergic-rhinitis; ‘Zyrtec’ (antihistamine) used for treating the symptoms of the season’s allergic-rhinitis, urticaria and perennial rhinitis; ‘Tussionex’ to provide respite from upper respiratory symptoms and cough; ‘Lortab’ as one of the rigorous pain killers. Among the many others from the long list of its products, mentioning their names only includes BUP-4, Edex, Elantan, Ferro Sanol, Uniretic, Univasc, Nipruss and Stogar.